VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31

Vanda Pharmaceuticals Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$4.09+0.06 (+1.49%)

Close on Oct 19, 2026

Market cap: $246.33M
P/E (TTM): –
Dividend yield: –

Vanda Pharmaceuticals Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	216	199	193	254	269	248	227	193	165	146	110	50	34	33	31	36	4.55
Cost of Revenue	13	11	15	24	26	23	24	21	–	–	23	1.58	–	0.13	–	2.89	1.92
Gross Profit	203	187	178	230	243	225	203	173	–	–	86	49	–	33	–	33	2.63
Research & Development	109	74	77	86	75	56	49	44	39	29	29	19	29	46	29	12	14
Selling, General & Admin	238	146	113	136	124	141	130	106	124	100	85	85	25	15	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	25	14	11	10	24
Advertising Expenses	29	1.90	0.50	2.60	6.70	13	3.20	0.90	1.30	1.40	3.40	5.00	0	0	–	–	–
Total Costs & Expenses	367	239	207	248	227	221	204	171	182	165	150	30	55	62	42	27	40
Operating Income	-151	-41	-14	6.33	42	27	23	22	-17	-19	-40	20	-21	-29	-11	8.84	-36
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.46	0.43	0.09
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	0.01	-1.22	-0.74	–	–
Asset Impairment Charges	0	0	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.02	–
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	78	–	–	–	–	–
Pretax Income	-139	-23	6.34	11	42	32	29	25	-15	-18	-40	20	-20	-28	-10	9.27	-36
Income Tax Expense	82	-4.02	3.83	5.03	9.21	8.32	-87	0.14	0.14	0.10	0	0	0	–	-0.44	2.08	–
Net Income	-220	-19	2.51	6.28	33	23	116	25	-16	-18	-40	20	-21	-29	-9.80	7.19	-36
EPS (Basic)(per share)	-3.74	-0.33	0.04	0.11	0.60	0.43	2.17	0.50	-0.35	-0.41	-0.94	0.58	-0.69	-1.01	-0.35	0.26	-1.33
EPS (Diluted)(per share)	-3.74	-0.33	0.04	0.11	0.58	0.42	2.11	0.48	-0.35	-0.41	-0.94	0.55	-0.69	-1.01	-0.35	0.25	-1.33
Shares Outstanding (Basic, Weighted)(shares)	59	58	57	56	56	54	53	51	45	43	42	35	30	28	28	28	27
Shares Outstanding (Diluted, Weighted)(shares)	59	58	58	57	57	55	55	53	45	43	42	37	30	28	28	29	27
EBITDA	–	–	–	–	–	–	–	–	–	–	–	21	-21	-29	-10	9.17	-36

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 93.7%
Operating margin: -86.1%
Net margin: -127.4%
Return on equity, FY2025: -50.9%

Financial strength

Current ratio: 1.61
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 34.1%

Valuation

P/E ratio: –
Price to sales: 1.14
Price to book: 1.12
Dividend yield: –